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Abstract This review deals with podocyte proteins that
play a significant role in the structure and function of the
glomerular filter. Genetic linkage studies has identified
several genes involved in the development of nephrotic
syndrome and contributed to the understanding of the
pathophysiology of glomerular proteinuria and/or focal
segmental glomerulosclerosis. Here, we describe already
well-characterized genetic diseases due to mutations in
nephrin, podocin, CD2AP, alpha-actinin-4, WT1, and
laminin β2 chain, as well as more recently identified
genetic abnormalities in TRPC6, phospholipase C epsilon,
and the proteins encoded by the mitochondrial genome. In
addition, the role of the proteins which have shown to be
important for the structure and functions by gene knockout
studies in mice, are also discussed. Furthermore, some rare
syndromes with glomerular involvement, in which molec-
ular defects have been recently identified, are briefly
described. In summary, this review updates the current
knowledge of genetic causes of congenital and childhood
nephrotic syndrome and provides new insights into mech-
anisms of glomerular dysfunction.
Keywords Nephrotic syndrome . Focal segmental
glomerulosclerosis . Podocytes . Nephrin . Podocin .
TRPC6 . PLCE1
The glomerular filtration barrier
The glomerulus consists of a cluster of capillaries appearing
in a looped formation supported by mesangial cells. While
blood plasma passes the glomerular capillary loops, the
local intracapillary pressure drives plasma through the
glomerular filtration barrier which consists of three layers
(Fig. 1).
First, the glomerular endothelial cells separate the blood
and tissue compartments. The endothelial cells are highly
flattened cells and regulate vasomotor tone and hemostasis
[4]. The role of the endothelial cells in selective filtration
seems not to be substantial since they are highly fenestrated
and highly permeable to water and small solutes. However,
a recent study has shown that morphological alterations in
the endothelial cell glycocalyx, making the cell surface
extremely negatively charged, have functional consequen-
ces for glomerular permeability [54]. Using the GAG-
degrading enzyme chondroitinase decreasing the thickness
of the endothelial cell glycocalyx resulted in an increase of
albumin clearance [54].
The endothelium is completely surrounded by the
second layer, the glomerular basement membrane (GBM).
This dense structure of extracellular matrix components
provides structural support for the capillary wall necessary
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to maintain local high blood pressure. The main compo-
nents of the GBM (collagen type IV, laminins, nidogen, and
proteoglycans) contribute to the selective permeability of
the GBM based on size and charge [72]. In the past years,
many studies were focussing on the structure of the GBM
because it was considered to be the leading part of the
glomerular filtration barrier. Although structural abnormal-
ities in the GBM may lead to proteinuria and hematuria, as
it occurs in Alport’s syndrome (mainly due to collagen IV
α5 chain mutations, but also collagen IV α3 and α4 chains)
or Pierson’s syndrome (due to laminin β2 mutations) [8,
146], the discovery of several novel proteins important for
glomerular permeability made the podocytes the favorite
candidate for constituting the main part of the glomerular
filtration barrier.
The podocytes, or visceral epithelial cells, represent the
third layer. They are highly specialized, terminally differ-
entiated cells with cytoplasmic extensions, the so-called
foot processes. Podocytes have an important role in size
and charge selective permeability, but also in synthesizing
and maintaining the GBM [98]. Furthermore, the fenestra-
tion of endothelial cells depends most notably on vascular
endothelial growth factor A secreted from differentiated
podocytes [4].
The foot processes of the podocytes attach to the outer
surface of the GBM through cell membrane receptors
(α3β1 integrins linked to talin, vinculin, and paxillin, and
α- and β-dystroglycans linked to utrophin; see Fig. 2) [68].
Adjacent foot processes interdigitate, forming a pore of
about 25–40 nm in width. This pore, or slit, is covered by a
membrane with a “zipper-like” structure [108]. Recently,
the structure of the slit membrane became the focus of
many studies, and although the complete structure is not
elucidated yet, several new proteins were found to be
important for its function. Many components of the slit
membrane are involved in the pathogenesis of (nephrotic
range) proteinuria.
Nephrotic syndrome—focal segmental
glomerulosclerosis
A nephrotic syndrome (NS) is defined by the occurrence of
heavy proteinuria, edema, and hypoalbuminemia, and is
classified as steroid-sensitive or steroid-resistant. In chil-
dren NS occurs most commonly at a young age, with a
peak incidence at 2 years. In most cases (~80%, according
to the International Study of Kidney Disease in Children
(1967–1974), ISKDC) patients have minimal change NS
(MCNS), which is characterized by responsiveness to
steroid treatment accompanied with more or less frequent
relapses. In 5–10% of NS patients (ISKDC) focal segmental
glomerulosclerosis (FSGS) is found [83, 128]. Less
frequent histologic lesions are mesangial proliferative
glomerulonephritis, membranoproliferative glomerulone-
phritis, and membranous glomerulopathy [83].
FSGS is a histological finding commonly seen in a large
variety of conditions with different underlying causes.
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Fig. 1 A cross-section (electron microscopy, original magnification
×30,000) of the glomerular filtration barrier with the capillary space
(Cs), urinary space (Us), endothelial cells (E), glomerular basement
membrane (BM), and podocytes (P)
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Fig. 2 Molecular anatomy of the podocyte slit membrane, schematic
representation. P paxillin, V vinculin, T talin, negatively charged
glycogalyx. Modified from [86], with permission
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These conditions share the focal (only some of the
glomeruli are involved) segmental (only part of an entire
glomerulus is involved) sclerosis of the glomerular capil-
lary tuft and manifests with proteinuria. As the disease
progresses, the sclerosis has a more diffuse and global
pattern. The biopsy may show mesangial deposits of
immunoglobulin M or complement C3 and hyaline deposits
all over the capillary loops [143]. Podocyte alterations (like
foot process effacement) are most notably in FSGS.
Recently, FSGS has been classified in five subcategories:
collapsing variant, tip lesion variant, cellular variant,
perihilar variant, and FSGS not otherwise specified (NOS)
[20, 22 for further reading]. Whether subdividing FSGS in
different subcategories gives insight in clinical features and
renal outcome is a subject of several reports recently
reviewed by D’Agati [21]. Collected data from adult
patients with biopsy proven FSGS showed a predisposition
of younger and more often African–American patients for
the collapsing variant of FSGS [131]. The collapsing and
tip variants usually manifest with more severe proteinuria
compared to the perihilar and NOS variants. Patients with
the last two morphologic variants tend to have higher blood
pressure and pathologically more arteriosclerosis [131]. As
far as renal outcome concerns, the patients with tip lesion
variant of FSGS seem more often to achieve complete
remission, whereas the collapsing variant of FSGS has
worse renal survival rates [131]. It is not excluded that
different morphologic variants represent different stages of
disease progression in FSGS.
FSGS commonly progresses to end-stage renal disease
(ESRD) requiring dialysis or renal transplantation. Post-
transplant recurrence occurs in 35–40% of patients with
idiopathic FSGS [2, 23], mainly a few days after
transplantation, and is often sensitive to plasmapheresis
and cyclophosphamide [3, 58, 116] treatment. The
recurrence may be due to a circulating plasma factor
[116]. This factor may be responsible for an increase in
podocyte integrin-linked kinase activity leading to podo-
cyte detachment from the GBM as found in some patients
[41]. Recently, cardiotrophin like cytokine-1 has been
identified as being a candidate for the FSGS permeability
factor [115].
Lately, the role of Notch signaling, which is involved in
the regulation of many cellular processes like proliferation,
differentiation, and cell death [50], in the development of
renal diseases is debated. Although NotchI protein plays a
crucial role during kidney development, very little active
NotchI can be detected in mature kidneys [134]. In
glomerular epithelial cells of patients with diabetic ne-
phropathy or FSGS, however, an increased presence of the
active protein domain of NotchI was found, which, based
on the homology with mouse podocyte biology [94], may
be involved in apoptosis induction.
Another classification of FSGS is based on the underly-
ing cause and subdivides it into three categories: idiopathic,
genetic, and secondary due to injury, medication, or drug
abuse [21, 143]. The last years genetic linkage studies have
identified several genes involved in the development of
FSGS and have contributed to the understanding of its
pathophysiology (Table 1). A subset of genes enlisted in
Table 1 are discussed below in more detail (Fig. 2).
NPHS1
One of the major components of the slit membrane is the
transmembrane protein nephrin (NPHS1, OMIM 602716).
Nephrin has an important role in maintaining the structure
of the podocyte slit membrane, as shown by nephrin-
deficient mice which develop proteinuria and foot process
effacement [103]. Injection of anti-nephrin antibody in
animals also results in foot process effacement [96].
Intracellularly, nephrin functions as a signaling molecule
[46, 47]. Nephrin (and also CD2AP, another component of
the slit membrane) associates with the p85 regulatory
subunit of phosphoinositide 3-OH kinase (PI3K) thereby
stimulating the AKT signaling pathway controlling cell
growth, migration, and survival [46].
Nephrin oligomers associate with lipid rafts in the slit
membrane [126]. A rat model of antibody-induced foot
process effacement showed morphological changes of the
filtration slits with apical dislocation and tyrosine phos-
phorylation of nephrin [126]. As such, tyrosine phosphor-
ylation may regulate the subcellular redistribution of slit
membrane proteins [7, 126]. Furthermore, a study in Fyn-
deficient mice showed an important role for tyrosine
phosphorylation in nephrin-dependent intracellular signal-
ing [133]. Fyn, a member of the Src protein kinase family,
tyrosine phosphorylates the cytoplasmic domain of nephrin
and Fyn-deficient mice develop proteinuria and foot
process effacement [133].
NPHS1 was found mutated in patients with the congen-
ital nephrotic syndrome of the Finnish type (CNF, OMIM
256300). CNF has an incidence of 1:10,000 births in
Finland, but less frequently in other countries. Although
several missense mutations were found in CNF patients,
two mutations, the Finmajor (deletion nucleotides 121 and
122) and Finminor (premature stop at amino acid 1109),
account for over 90% of the cases in Finland [59].
Recurrence of CNF may occur in 20–25% of the patients
after receiving a renal allograft and may be caused by anti-
nephrin antibodies [97, 137]. In addition to the renal
disease, patients with NPHS1 mutations may also show
neurological symptoms including muscular hypotonia,
dyskinesia, mild cerebral atrophy, and hearing impairment
of still obscure origin [70].
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Table 1 Characteristics of hereditary diseases involved in nephrotic syndrome
List of
diseases
Mode of
inheritance
Protein Protein
function
Gene Chrom. Protein
expression slit
membrane
Congenital nephrotic
syndrome of the
Finnish type (CNF)
Autosomal
recessive
Nephrin Key component of the
podocyte slit
diaphragm
NPHS1 19q13.1 Podocyte slit
membrane
Steroid-resistant
nephrotic syndrome
(SRN1)
Autosomal
recessive
Podocin Establishment of the
podocyte slit
diaphragm
NPHS2 1q25–q31 Podocyte slit
membrane
Familial FSGS Autosomal
recessive
CD2-associated
protein
Cytoskeletal
remodeling, cell
motility, endocytosis
CD2AP 6 Podocyte slit
membrane
Familial focal
segmental
glomerulosclerosis
(FSGS1)
Autosomal
dominant
Alpha-actinin-4 Anchoring protein ACTN4 19q13 Predominantly
podocyte cell body
Denys-Drash
syndrome (DDS)/
Frasier syndrome
(FS)
de novo
(dominant)
Wilms tumor 1 Transcription factor WT1 11p13 Nucleus and
cytoplasm of
podocyte cell body
Familial focal
segmental
glomerulosclerosis
(FSGS2)
Autosomal
dominant
Transient receptor
potential cation
channel 6
Ca2+entry during cell
proliferation
TRPC6 11q21–q22 Tubules, podocytes,
mesangial and
endothelial cells
Early-onset familial
nephrotic syndrome
Autosomal
recessive
Phospholipase C
epsilon
Involved in cell
growth and
differentiation, gene
expression
PLCE1 10q23 Cytoplasm podocyte
cell body
Pierson’s syndrome Autosomal
recessive
Laminin β2 chain Establishment of the
glomerular basement
membrane
LAMB2 3p21 Glomerular basement
membrane
Mitochondrial
disorder
Maternal Non-protein tRNA Amino acid supply NA mtDNA Mitochondrion
renal cells
CoQ10 deficiency Autosomal
recessive
Parahydroxy-
benzoate-
polyprenyl-
transferase
Electron carrier in
mitochondrial
respiratory chain
COQ2 4q21.23 Mitochondrion
renal cells
Nail-patella syndrome de novo
(dominant)
LIM homeobox
transcription factor
1 beta
Transcription factor LMX1B 17q11 Nucleus and
cytoplasm of
podocyte cell body
Schimke immuno-
osseous dysplasia
Autosomal
recessive
SWI/SNF2-related,
matrix-associated,
actin-dependent
regulator of
chromatin,
subfamily a-like 1
Gene regulation,
replication,
recombination, and
DNA repair
SMARCAL1 2q34–q36 Nucleus of podocyte
cells and proximal
tubule
Mandibuloacral
dysplasia
Autosomal
recessive
Zinc metallo-
proteinase
STE24
Potentially involved in
processing of
farnessylated protein
ZMPSTE24 1p34 Unknown
Galloway-Mowat
syndrome
Autosomal
recessive
GMS1 unknown GMS1 Unknown Podocytes
Fechtner syndrome Autosomal
dominant
Nonmuscle
myosinllA
heavy chain
Actin-based motility MYH9 22q12.3 Tubular epithelia,
mesangial cells and
podocyte
Action myoclonus-
renal failure
syndrome
Autosomal
recessive
Lysosomal integral
membrane protein
type 2
Lysosomal degradation
of macromolecules,
RNA and DNA
SCARB2 4q13–21 Lysosomal membrane
of glomerular cells
(study in mice)
Chrom. chromosome, NA not applicable, mtDNA mitochondrial DNA, GBM glomerular basement membrane, FP foot process, NS nephrotic
syndrome, ESRD end-stage renal disease, FSGS focal segmental glomerulosclerosis, DMS diffuse mesangial sclerosis
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NPHS2
Podocin (NPHS2, OMIM 604766), a member of the
stomatin protein family, is exclusively expressed in the
podocytes and localizes at the insertion of the slit
membrane. Due to its similarity to stomatin, it is believed
that podocin forms a hairpin-like structure with intracellular
NH2- and COOH-termini [13, 109].
Podocin, like nephrin, associates with lipid rafts [121],
and recruits nephrin and CD2AP in these rafts ensuring a
stable and proper functioning filtration barrier. The COOH-
terminal cytoplasmic tail of podocin interacts with nephrin
and Cd2ap (the mouse homolog) [121]. This protein
interaction greatly enhances nephrin-induced signaling in
vitro [47]. The COOH-terminal domain of podocin also
binds NEPH-1, a podocyte slit membrane protein structur-
ally related to nephrin [122]. NEPH-1 is involved in
maintaining the structure of the filtration barrier and also
interacts with nephrin [75].
Podocin dysfunction leads to alterations of the slit
membrane assembly and to proteinuria in experimental
models. NPHS2−/− mice develop proteinuria and massive
mesangial sclerosis (different from FSGS seen in humans),
the podocytes are enlarged and focally vacuolized. The
sclerosis rapidly progresses with age. Beside the absence of
podocin, no nephrin is found in the foot processes as well.
The podocin-deficient mice die a few days after birth [110].
In human, NPHS2 mutations, are mainly associated with
autosomal recessive steroid-resistant nephrotic syndrome
(SRN1, OMIM 600995) [70], but were also found in
sporadic cases of steroid-resistant nephrotic syndrome
patients [16, 57, 67, 132]. A recent study has demonstrated
that also milder NPHS1 mutations can cause a childhood-
onset steroid-resistant nephrotic syndrome with underlying
histological lesions ranging from minimal change nephrop-
athy to FSGS [101].
The podocin variant R229Q is often found and has an
allele frequency of 3.6% in a control population. The
mutant protein has a decreased binding efficiency to
nephrin and enhances FSGS susceptibility in association
with a second NPHS2 mutation [132]. The R229Q variant
is also associated with microalbuminuria in the general
population [100].
Mutated podocin may cause a disturbance in recruiting
nephrin to the plasma membrane [49, 111], which is
comparable with the lack of nephrin in the slit membrane
found in podocin-deficient mice [110]. The R138Q NPHS2
mutant (one of the most common found mutation) results in
retainment of the mutant podocin in the endoplasmatic
reticulum. The R138X NPHS2 mutant yields a mutant
podocin protein that is not able to associate with lipid rafts
in the plasma membrane. Both mutant proteins were unable
to recruit nephrin to the lipid rafts and lost their ability to
enhance nephrin signaling [49, 111]. NH2-terminal mutant
proteins were still able to associate with lipid rafts and had
no effect on nephrin localization [95]. Collected clinical
data from patients with NPHS2 mutations showed that
podocin mutants retained in the endoplasmatic reticulum
are associated with earlier onset of the disease than those
correctly targeted to the cell membrane [111].
Early reports showed that patients with NPHS2 muta-
tions had no recurrence of FSGS after renal transplantation.
Now it is believed that patients with NPHS2 mutations have
a lower risk for recurrent FSGS after renal transplantation
compared to patients with idiopathic FSGS [10, 112, 139].
Patients carrying a heterozygous NPHS2 mutation show a
higher risk for recurrent FSGS (five out of eight published)
in contrast to patients with homozygous or compound
heterozygous mutations (five out of 68 published) [17]. The
authors state that grafts from carriers of NPHS2 mutations,
such as from parents, should be avoided because of the
higher risk of recurrent FSGS. Furthermore, carriers of
heterozygous NPHS2 mutations should be strictly moni-
tored in the post-graft phase [17].
CD2AP
Although first found in a yeast two-hybrid screen as a
protein binding to the T-cell membrane protein CD2 during
cell–cell interaction [28], an important role for Cd2ap
(CD2-associated protein) in the kidney became evident
when Cd2ap knockout mice died because of renal failure
involving the glomerulus [125]. The Cd2ap−/− mice died at
an age of 6 to 7 weeks, but already at 1 week glomeruli
were increased in size and cellularity (mesangial cell
proliferation and glomerulosclerosis) and electron micros-
copy showed extensive foot processes effacement [125].
Cd2ap+/− mice showed no proteinuria, but have an
increased susceptibility to glomerular injury by immune
complexes and nephrotoxic antibodies [60]. At 9 months of
age, glomerular lesions were present with an increase in
mesangial cellularity. Some lesions were similar to human
FSGS and for this reason primary FSGS patients were
tested for mutations in the CD2AP gene (the human
homolog of Cd2ap, originally named CMS, OMIM
604241) [60] One heterozygous splice-site mutation was
detected in two patients. The predicted mutated protein
would lack more than 80% of the protein. Immunoblotting
CD2AP isolated from immortalized B-lymphocytes showed
a reduction in CD2AP expression in these patients [60].
Beside the heterozygous splice-site mutation one homozy-
gous CD2AP mutation has been described [77]. This
mutation results in a premature stop codon and a protein
truncation of 4% at the COOH-terminus. No CD2AP
protein was found in the patients’ lymphocytes. Both
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parents, who are heterozygous for the mutation, show no
kidney pathology and no decrease in CD2AP expression in
lymphocytes. These two different reports show that not all
heterozygous CD2AP mutations cause kidney disease. The
development of FSGS clearly depends on the severity of
the mutation [77].
CD2AP/Cd2ap is a multifunctional adaptor molecule
localized to the cytoplasm, membrane ruffles, and leading
edges of cells [61]. The protein plays a role in cytoskeletal
remodeling [28, 61], cell survival [46, 118], and endocy-
tosis [19, 63, 80]. The COOH-terminus of CD2AP directly
interacts with the cytoskeletal protein filamentous actin
(F-actin) [61, 71] and synaptopodin, an actin-bundling
protein [48]. At the slit membrane, CD2AP interacts with
nephrin and podocin [121, 124] and serves as a linker
anchoring slit membrane proteins to the actin cytoskeleton
of podocytes.
CD2AP and nephrin bind to the p85 regulatory subunit
of phosphoinositide 3-OH kinase (PI3K) stimulating the
serine–threonine kinase AKT [46]. One of the target
proteins of AKT is Bad, a proapoptotic Bcl2 family
member that interacts with prosurvival Bcl2 family mem-
bers to promote apoptosis. Phosphorylated Bad is inactive
and protects podocytes against detachment-induced cell
death [46].
Combined mutations in two podocyte genes may be a
common etiology for glomerular disease [48]. Crossbreed-
ing heterozygous Cd2ap knockout mice with mice hetero-
zygous (knockout) for synaptopodin or Fyn, which alone
did not result in clinical kidney pathology, resulted in
spontaneous proteinuria and FSGS-like glomerular damage
supporting a role for CD2AP haploinsufficiency [60]. A
role of combined mutations in the development of
glomerular disease is also seen in a patient group with
non-familial childhood-onset FSGS. One patient showed a
CD2AP mutation combined with a heterozygous NPHS2
mutation [76].
ACTN4
Alpha-actinin-4 (ACTN4, OMIM 604638) is an actin-
bundling protein important for the integrity of the podocyte
cytoskeleton associated with cell motility. Transgenic
ACTN4 mice develop a severe glomerular disease and
FSGS [66, 86]. Lymphocytes of homozygous ACTN4-
deficient mice displayed an increase in lymphocyte chemo-
taxis, supporting the role of ACTN4 in cell motility [66].
Podocyte cell lines derived from these ACTN4-deficient
mice show less adherence to the GBM components
collagen IV and laminins-10 and laminins-11, also indicat-
ing its role in maintaining glomerular architecture and
preventing disease [24].
ACTN4 is highly expressed in several human tissues.
Despite the overall expression of ACTN4, the human
phenotype associated with ACTN4 mutations only mani-
fests in the kidney. Mutations in ACTN4 are associated with
an autosomal dominant form of familial FSGS (OMIM
603278). By now, only three ACTN4 missense mutations
have been described in literature [55, 140]. The mutated
ACTN4 proteins showed a higher binding affinity to F-
actin, and may change the mechanical characteristics of the
podocyte [55]. In vitro studies in podocytes of mice
homozygous for the human disease-causing K225E substi-
tution, shows aggregation of the mutant α-actinin-4 with F-
actin. Furthermore, the conformational change also leads to
an increase of the actin-binding stoichiometry and a
resistance to regulation by Ca2+ [141]. In sporadic cases
of FSGS, without an apparent familial disease pattern,
ACTN4 amino acid substitutions were also found [140].
However, cellular localization of the mutated proteins and
actin-binding assays show that these mutations are probably
not disease-causing or contributing to the disease [140].
WT1
Another well-described genetic defect in patients with
primary nephrotic syndrome is the spectrum of clinical
pictures caused by mutations in WT1 (for review 74, 90,
135, OMIM 607102), a transcription factor regulating
several programs of cellular proliferation and differentiation.
The WT1 gene is positionally cloned based on its role in the
development of Wilms tumors (OMIM 194070), the most
common form of cancer in children [33, 38]. Heterozygous
de novo mutations in WT1 cause Denys-Drash syndrome
(DDS, OMIM 194080) and Frasier syndrome (FS, OMIM
136680), two overlapping syndromes [84], characterized by
nephrotic syndrome with either diffuse mesangial sclerosis
(DMS in DDS) or FSGS (in FS), genitourinary defects, and
a higher risk of developing Wilms tumor (in DDS) or
gonadal dysgerminoma (in both DDS and FS).
WT1 has a transcription-regulating domain (encoded by
exons 1 to 6) and a DNA-binding zinc finger domain
(encoded by exons 7 to 10). There are four major isoforms
due to the insertion of the amino acids KTS between zinc
fingers 3 and 4 (alternative splice site directly situated after
exon 9), and due to the insertion of 17 amino acids
completely encoded by exon 5. The insertion/deletion of
KTS influences the space between zinc fingers 3 and 4 and
thereby the binding properties of the protein [39].
The mutations found in DDS patients, but also in cases
of isolated DMS, are mostly missense mutations (80%) in
zinc fingers 2 and 3 (exon 8 and 9). The R394W (1180
C>T, exon 9) substitution is most frequently found in
almost 50% of the DDS patients [14, 74, 99]. These
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mutations affect the DNA-binding stability of WT1 to the
target gene [73]. FS patients usually present with intron 9
splice-site mutations affecting the +KTS/−KTS ratio [6,
62]. The fact that DDS and FS are overlapping syndromes
is strengthened by the finding of intron 9 splice-site
mutations in patients with a phenotype of DDS [25, 39,
53, 84], and an exon 9 mutation in a patient with FS [64].
TRPC6
Transient receptor potential cation channel subfamily C, 1-7
(TRPC) is a subgroup of the TRP family of cation channels
involved in the regulation of Ca2+ influx. These ion
channels can be activated subsequent to either depletion
of Ca2+ from internal stores or through receptor-mediated
processes [107]. TRPC channels are expressed in many
tissues. In the podocytes TRPC-1, TRPC-2, TRPC-5, and
TRPC-6 are expressed [106]. TRPC6 (OMIM 603652) is
localized to the podocyte cell body, primary processes and
in close vicinity to the slit membrane were it interacts with
nephrin and podocin (not CD2AP) [106]. TRPC6 is also
abundantly expressed in mesangial cells [127]. In diabetic
nephropathy, the mesangial contractile function is impaired,
most probably due to a reduced Ca2+ influx. A recent study
showed that high glucose downregulates the TRPC6 protein
which might contribute to the impaired Ca2+ signaling of
mesangial cells seen in diabetes [36].
TRPC6 was found mutated in families with an autosomal
dominant form of FSGS (OMIM 603965) [106, 142]. These
mutations may cause a gain of function. The P112Q mutated
TRPC6 protein showed an enhanced influx of Ca2+,
especially after activation of the G-protein-coupled receptor
AT1 by angiotensin II, and the cellular localization of the
mutant protein is more situated at the plasma membrane
[142]. An increase in Ca2+ influx is also seen in two other
missense mutations (R895C and E897K), but absent in three
different ones (N143S, S270T, and K874X) [106]. In these
cases an altered channel regulation or an altered interaction
with other slit membrane proteins (like nephrin and podocin)
may cause the disease [106]. In addition to the effects of
gain-of-function mutations in the TRPC6 gene, also elevated
levels of wild-type TRPC6 protein in some acquired
glomerular diseases (like membranous nephropathy and
puromycin aminonucleoside-induced albuminuria) may lead
to podocyte dysfunction [88]. The pathways that TRPC6
may modulate are discussed in a recent seminar [119].
PLCE1
PLCE1 (phospholipase C epsilon, OMIM 608414) belongs
to the phospholipase C (PLC) family involved in intracel-
lular signaling, necessary for cell growth and differentia-
tion. PLC plays an important role in regulating the Ca2+
release from internal stores as well as the influx of Ca2+
through cation channels (like TRPC). PLC is activated by
binding of a hormone or growth factor to its receptor and
PLC in turn converts phosphatidylinositol-4,5-bisphosphate
into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol.
Plasma membrane channels are activated and cations flow
into the cell [31].
In the kidney, PLCE1 expression is found in the
podocyte cell body and foot processes [43]. PLCE1
expression appears at the S-shaped stage of glomerular
development and is highly expressed during the early
capillary loop stage [43]. Recently, positional cloning
identified the PLCE1 gene being involved in families with
early-onset NS and ESRD (OMIM 610725) [43]. Renal
histopathology generally shows DMS and histochemistry
reveals reduced nephrin expression. In two patients (carry-
ing the nontruncating missense mutation S1484L) biopsies
revealed FSGS. In these patients the age of onset was
relatively late as was the age of reaching ESRD [43]. A
recent study in patients with isolated (non-syndromic)
DMS, showed that PLCE1 truncating mutations are more
frequently found than mutations in WT1 or LAMB2, two
genes known to cause isolated DMS as well [32]. The
authors speculate that missense mutations in PLCE1 may
be associated with a milder disease course in isolated DMS
or other histologic variants such as FSGS [32, 43].
A zebrafish knockdown model was used to investigate the
role of PLCE1 in the maintenance of the podocyte filtration
barrier during development. The zebrafish PLCE1 ortholog
was knocked-down in embryo’s using antisense morpholino
oligonucleotides and barrier function was assayed at 4-day-
old embryos by vascular retention of a large FITC-labeled
tracer molecule. In control embryos, the tracer molecule
retained in the vasculature. Morpholino-injected embryos
showed abundant FITC-positive endocytic vesicles in the
pronephric tubule, distal to the glomerulus. This indicated a
breakdown of the barrier function in the pronephric
glomerulus [43].
Laminin β-2
The heterotrimeric laminin is assembled by three polypeptide
chains: α, β, and γ. Different isoforms have been identified.
Laminin-11 (α5β2γ1) is predominantly found in the adult
GBM and replaces the laminin-1 (α1β1γ1) isoform, initially
expressed during kidney development [129].
Mutations in the LAMB2 gene, encoding the laminin β2
chain (OMIM 150325), are associated with the Pierson’s
syndrome (OMIM 609049). This syndrome is characterized
by early-onset nephrotic syndrome with DMS rapidly
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progressing to ESRD and distinct ocular abnormalities (in
particular microcoria) [146]. The LAMB2 mutations result
in loss of laminin-β2 expression in the kidney and other
tissues studied [146]. Mutations were also found in patients
with congenital nephrotic syndrome (and FSGS) with or
without minor ocular changes [40]. These results indicate
genotype–phenotype correlations among patients with
LAMB2 mutations. The authors speculated that complete
loss-of-function (e.g. truncating) mutations appear to be
associated with the complete Pierson syndrome, whereas
missense mutations may display variable phenotypes
ranging from a milder variant of Pierson’s syndrome to
isolated congenital nephrotic syndrome with or without
minor ocular abnormalities [40]. The frequency of hematu-
ria in these patients is not clear from the clinical data.
Mitochondrial disorders
Mitochondrial cytopathies, either caused by mutations in
the maternally inherited mitochondrial DNA (mtDNA) or in
nuclear DNA, represent a heterogeneous group of multi-
system disorders [120]. Mitochondria are non-uniformly
distributed in tissues and mutated and wild-type mtDNA
coexist in cells (heteroplasmy). These characteristics con-
tribute to the large variety of clinical symptoms seen in
mtDNA mutations [120].
Mutations in the tRNALeu(UUR) (OMIM 590050)
gene are mainly associated with the MELAS syndrome
(mitochondrial myopathy, encephalopathy, lactic acidosis,
and stroke-like episodes, OMIM 540000) [102]. The most
common transition A3243G is also found in patients with
FSGS sometimes associated with maternally inherited
diabetes and/or sensorineural hearing loss [18, 27, 37,
44, 52, 69, 92, 144]. In most patients proteinuria is below
nephrotic range and the FSGS progresses slowly.
The effect of the A3243G mutation to the function of the
tRNALeu has been studied [145]. A3243G mutant tRNALeu
have a shorter life span and the extent of aminoacylation
(“charging” of a tRNA with an amino acid) was rather low
(less than 30%) compared to wildtype [145].
Mutations were also found in other mitochondrial tRNA
genes. In one patient, a A5843G transition was found in the
tRNATyr (OMIM 590100) gene. The patient presented with
mitochondrial cytopathy preceded by steroid-resistant
FSGS. A skeletal muscle biopsy showed a combined
respiratory chain deficiency and a partial deficiency of
coenzyme Q10 most probably secondary to the oxidative
damage [117]. Finally, the A4269G substitution in the
tRNAIle gene (OMIM 590045) is described in a patient with
mitochondrial encephalomyopathy and multi-organ disor-
ders including deafness, epilepsy, FSGS, and dilated
myopathy later in life [130].
Coenzyme Q10 (CoQ10) plays an important role in the
electron transport from complex I and II to complex III of
the mitochondrial respiratory chain. Coenzyme CoQ10
deficiency (OMIM 607426) is associated with a variety of
clinical phenotypes. Recently, a mutation in the nuclear
DNA was found in a patient with CoQ10 deficiency [104].
This patient presented at age 12 months with proteinuria
due to FSGS, mild psychomotor delay, and optic atrophy.
Homozygosity mapping revealed a homozygous mutation
in the COQ2 gene, encoding para-hydroxybenzoate-
polyprenyl-transferase (OMIM 609825), an enzyme in-
volved in the CoQ10 biosynthetic pathway [104]. The
pathogenity of the mutation was demonstrated by comple-
mentation experiments in COQ2-deficient yeast and
showed full functional complementation after transforma-
tion with wild-type COQ2 but not mutant COQ2 [78]. This
genetic defect of the respiratory chain, is related to late-
onset nephrotic syndrome with multiple organ involvement.
However, respiratory chain deficiency has also been
reported in one infant with congenital nephrotic syndrome
characterized by diffuse mesangial hypercellularity and
focal tubular dilation [35] and in one infant with glomerular
lesions characterized by crescentic glomerulonephritis [26].
The encephalopathy in patients with primary CoQ10
deficiency may be improved by oral CoQ10 supplementa-
tion. Recently, it is shown that early administration of
CoQ10 may also result in progressive recovery of the renal
function and reduction of proteinuria [89].
Other rare cases of hereditary FSGS and recent findings
The nail-patella syndrome (OMIM 161200) is a rare
autosomal dominant disorder characterized by dysplasia of
the nails, absent or malformed patellas, dysplasia of the
elbows and frequently glaucoma and progressive nephrop-
athy. Renal biopsies reveal non-specific findings mostly
related to the degree of renal failure, including FSGS,
proliferative glomerulonephritis with crescent formation,
and hyalinization of the glomeruli [12]. The gene involved
is the transcription factor LMX1B (OMIM 602575) which,
among others, is required for expression of CD2AP protein
and podocin [87].
Mutations in SMARCAL1 (OMIM 606622) are in-
volved in the development of Schimke immuno-osseous
dysplasia (OMIM 242900). This autosomal recessive
disorder is characterized by spondyloepiphyseal dysplasia
causing growth retardation, defective cellular immunity,
hyperpigmented macules, dysmorphic facial feature, and
nephrotic syndrome (due to FSGS). SMARCAL1 encodes
an actin-dependent regulator of chromatin which is
involved in gene regulation, replication, recombination,
and DNA repair [11]. More detailed studies of its role are
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provided by Elizondo et al. [29]. Recently, mutations in
SMARCAL1 were also found in two siblings with an
incomplete phenotype of Schimke immuno-osseous dys-
plasia. The siblings were initially classified as suffering
from familial steroid-resistant nephrotic syndrome. In
prepuberty they had proportionate short stature which
developed into disproportions during adolescence. No
other syndrome-specific symptoms were found. Milder
phenotypes may be clinically overlooked [147]. It has
been demonstrated that anthropometric measures are
helpful to distinguish Schimke immuno-osseous dysplasia
from other forms of chronic kidney disease [79].
In three patients (of two families) a nonsense mutation in
tetraspanin CD151 (OMIM 602243) causes end-stage
familial nephropathy with pretibial epidermolysis bullosa
and sensorineural deafness (OMIM 609057). The only
available renal biopsy of one patient did not show FSGS
but splitting of the tubular basement membrane and
thickening and fragmentation of the GBM [56]. CD151
null mice, however, develop massive proteinuria while
aging caused by FSGS [113].
Mandibuloacral dysplasia (MAD, OMIM 248370/
608612) is a rare autosomal recessive syndrome with
variable clinical features. These features include mandibular
and clavicular hypoplasia, acro-osteolysis of terminal
phalanges, delayed closure of cranial sutures, joint con-
tractures, mottled pigmentation, and lipodystrophy. MAD is
also genetically heterogeneous: two loci have been identi-
fied. So far, most mutations were found in LMNA, encoding
lamin A (OMIM 150330), a structural protein component
of the nuclear lamina determining nuclear shape and size
[51]. Only three patients have been reported with com-
pound heterozygous mutations in ZMPSTE24 (OMIM
606480). This gene encodes a zinc metallo-proteinase
involved in post-translational processing of prelamin A.
Two of them presented with renal failure caused by FSGS,
suggesting FSGS as a phenotypic manifestation in patients
with ZMPSTE24 deficiency [1].
The Galloway-Mowat syndrome (GMS, OMIM 138770)
is an autosomal recessive disorder characterized by micro-
cephaly, severe mental retardation, hiatal hernia, and steroid-
resistant nephrotic syndrome. In GMS, the nephrotic
syndrome occurs in the first 4 months of life, is steroid-
resistant and rapidly progresses to end-stage renal disease.
Histology shows heterogeneous lesions: minimal changes,
endocapillary proliferation, FSGS (in most cases), and, in
end stages, DMS [114]. Recent linkage studies in two
Algerian families identified a homozygous mutation in the
GMS1 gene. The protein encoded by this gene is expressed
in many tissues, including brain and glomerular podocytes,
and has yet an unknown function [148].
Recently, MYH9 and SCARB2 have been identified as
being involved in the development of FSGS. MYH9
encodes for the heavy chain of nonmuscle myosinIIA
(NMMHC-IIA, OMIM 160775). Myosins of class II are
widely distributed in most tissues and are essential
components of the cell motor system involved in several
important cell functions. These, among others, include
phagocytosis, maintenance of cell shape and polarity, and
intracellular organelle/particle trafficking [81]. Nonmuscle
myosinII is composed of two heavy chains and two pairs of
light chains. The NH2-terminal region contains an actin and
ATP-binding domain required for motor activity. The
COOH-terminus allows the molecules to form filaments
[123]. In the kidney, NMMHC-IIA is localized in the
tubular epithelia and in the glomeruli it is expressed in
podocytes and mesangial cells [34].
Heterozygous mutations of MYH9 are involved in a
complex disorder named MYH9-related disease character-
ized by platelet macrocytosis, thrombocytopenia, and
leukocyte inclusions containing NMMHC-IIA. Complica-
tions that may arise are deafness, cataracts, and renal
failure. In the past, these patients were classified as being
affected by May–Hegglin anomaly, Sebastian syndrome,
Fechtner syndrome, or Epstein syndrome (OMIM 155100,
605249, 153640, and 153650, respectively). It is now
believed that these disorders are not distinct entities, but
rather a single illness with a continuous clinical spectrum
[81]. In a large family with Fechtner syndrome, ten
members carried a MYH9 missense mutation. Only two
members had renal problems. Electron microscopy showed
FSGS and segmental effacement of podocytes in these
patients [34]. Why the other family members did not
develop renal problems remains unclear. Most probably
other additional factors play a role [34, 65]. More recently,
MYH9 was suggested to be a risk gene for the development
of idiopathic FSGS by usage of a genome scan on African–
American individuals with FSGS. However, sequencing of
the 40 exons and intron–exon junctions of MYH9 did not
reveal any causal sequence variation. The authors hypoth-
esize that the variation may occur in regulatory elements or
splice-site determinants influencing RNA expression or
protein structure [65]. Future studies are necessary to
identify the precise role of MYH9 in the development of
FSGS.
Action myoclonus-renal failure (AMRF, OMIM 254900)
syndrome is a lethal inherited form of progressive myoc-
lonus epilepsy associated with renal failure due to FSGS. It
usually starts at 15–25 years of age with proteinuria or
neurological symptoms as tremor, action myoclonus, or
seizures associated with storage material in the brain [9].
Mutations in SCARB2 (OMIM 602257) were found in three
families with a single AMRF proband [5, 9]. However,
analysis of patients with non-syndromic FSGS, MCNS,
thin-basement membrane nephropathy, or non-Alport with
hematuria and proteinuria did not reveal any mutations
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indicating a specific role of SCARB2 in AMRF [9].
SCARB2 encodes for the ubiquitously expressed lysosomal
integral membrane protein type 2 (LIMP-2) mainly found
in lysosomes and late endosomes [5]. This LIMP-2 protein
has been shown to act as a receptor to bind β-
glucocerebrosidase, the enzyme defective in Gaucher
disease (lysosomal storage disorder) [105]. LIMP-2 defi-
cient mice have also a kidney phenotype. The kidneys,
which are non-hydronephrotic show pelvi-ureteric obstruc-
tion and glomerular lesions with mesangial hypercellularity
and effacement of foot processes [9].
Conclusion
In the last years, knowledge of the genetic defects described
above provided new insight in the structure and function of
the podocyte slit membrane and the development of
nephrotic syndrome. FSGS patients are a heterogeneous
group with different underlying causes. Although the
development of FSGS is not completely and solely explained
by the presence of genetic abnormalities, the knowledge
whether a FSGS patient carries a genetic defect turns out to
be very important for determining treatment strategy and
prognosis of the individual patient. For example, most of the
patients with NPHS2 mutations are steroid-resistant and
therefore treatment with steroids may be discontinued after
obtaining the results of DNA analysis. Furthermore, in most
cases, there is no recurrence of nephrotic syndrome after
renal transplantation in patients with NPHS2 mutations. In
patients carryingWT1 mutations further medical examination
and regular check-ups are required given the higher risk of
developing malignancies. Mitochondrial DNA mutations
may cause multi-systemic disorders requiring regular neuro-
logical follow-up and glycemia control. Finally, combined
genetic defects in podocyte genes may play a role in the
development of FSGS.
How to approach a patient with steroid-resistant nephrotic
syndrome with FSGS in the biopsy? FSGS is not a specific
histopathologic lesion. Similar alterations may be observed in
a lot of other disorders [93] which should be excluded. When
a hereditary disorder is suspected (a familial occurrence is
not required) careful clinical and biochemical investigations
could direct the research (neurologic symptoms, bone, eye,
ear, genital abnormalities, thrombocytopenia). As the next
step, the analysis can start with screening for the most
frequent genetic disorders, taking the date of the first
manifestation of the nephrotic syndrome in consideration.
However, this frequency depends on the country of origin. It
is not known for all genes. For NPHS2 an extensive
evaluation was made by Berdeli et al. [15]. The incidence
of podocin mutations in familial steroid-resistant nephrotic
syndrome was found to be 29.2% in Turkey, being 40% in
European and American children, and 0% in Japanese and
Korean children. The incidence of sporadic podocin muta-
tions in Turkey (24%) was similar to that in European and
American children (10–30%), but higher than in Chinese
(4%) and Japanese and Korean children (0%). NPHS1
mutations are frequent in Finland. Two thirds of cases of
nephrotic syndrome in the first year of life in a large
European cohort are caused by mutations in four genes
(NPSH1, NPSH2, WT1, and LAMB2) [42].
Further studies of the numerous podocyte genes coming
from human and animal studies will undoubtfully identify
new players on the edge of glomerular filtration barrier and
will provide new insights into the pathogenesis of nephrotic
syndromes in humans. The insight in the podocyte function
obtained from the study of these genetic disorders will help
to explain the effect of medication used in the treatment of
glomerular disorders. Most drugs used in the treatment of
nephrotic syndrome have a direct effect on the podocytes
(corticoids [136], inhibitors of angiotensin-converting en-
zyme [45], COX2 inhibition [138], mizoribine [91], and
cyclosporine [30]). The antiproteinuric effect of cyclospor-
ine attributed to its immunosuppressive action, may also
result from stabilization of the actin cytoskeleton in the
podocyte. Cyclosporine protects synaptopodin from cathep-
sin l-mediated degradation. Synaptopodin is an important
regulator of podocyte function (see Fig. 2) [82]. Recent
studies in the action of cyclosporine, frequently used in the
treatment of FSGS [85], highlight this new concept [30].
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